Machetti M, Majabo M J, Furfaro E, Solari N, Novelli A, Cafiero F, Viscoli C
Advanced Biotechnology Center, Largo R. Benzi 10, 16132 Genova, Italy.
J Antimicrob Chemother. 2006 Oct;58(4):806-10. doi: 10.1093/jac/dkl334. Epub 2006 Aug 30.
The association between piperacillin/tazobactam and the positivity of the galactomannan (GM) detection ELISA test is well described. Little information is available about the kinetics of GM in patients treated with piperacillin/tazobactam. The present study aimed at clarifying the baseline interaction between piperacillin/tazobactam and GM in patients receiving this drug.
Seven patients undergoing abdominal surgery received perioperative prophylaxis with piperacillin/tazobactam. Each patient received three doses of 4.5 g of the drug, administered at 8 h intervals (one before and two after surgery). Three patients received antibiotic batches with 'medium' (GM-index = 1.782) and four patients received antibiotic batches with 'high' (GM-index = 6.665) GM content. Serum samples for GM evaluation were collected before drug infusion and at times +1, +3, +6 and +8 h after the first and third infusions.
GM levels increased after infusion, in particular when batches with 'high' GM content were used. Moreover, a non-statistically significant increase between the first dose and the third dose was observed. All samples taken >6 h after administration were negative (GM-index < 0.2), both with the 'medium' and the 'high' GM content batches.
The low content of GM 8 h after piperacillin/tazobactam infusion suggests that in non-neutropenic cancer patients with solid tumours receiving up to three doses of piperacillin/tazobactam, serum sampling for GM detection should be performed immediately before the next piperacillin/tazobactam administration.
哌拉西林/他唑巴坦与半乳甘露聚糖(GM)检测酶联免疫吸附测定(ELISA)试验阳性之间的关联已有充分描述。关于接受哌拉西林/他唑巴坦治疗患者体内GM的动力学信息较少。本研究旨在阐明接受该药物治疗的患者中哌拉西林/他唑巴坦与GM之间的基线相互作用。
7例接受腹部手术的患者接受了哌拉西林/他唑巴坦围手术期预防用药。每位患者接受3剂4.5 g该药物,每隔8小时给药一次(术前1剂,术后2剂)。3例患者接受了GM含量“中等”(GM指数=1.782)的抗生素批次,4例患者接受了GM含量“高”(GM指数=6.665)的抗生素批次。在药物输注前以及第一次和第三次输注后的1、3、6和8小时采集用于GM评估的血清样本。
输注后GM水平升高,尤其是使用GM含量“高”的批次时。此外,观察到第一剂和第三剂之间有非统计学意义的升高。给药后>6小时采集的所有样本均为阴性(GM指数<0.2),无论GM含量是“中等”还是“高”的批次。
哌拉西林/他唑巴坦输注8小时后GM含量较低,这表明在接受最多3剂哌拉西林/他唑巴坦的实体瘤非中性粒细胞减少癌症患者中,应在下一次哌拉西林/他唑巴坦给药前立即采集血清样本进行GM检测。